Series B results in $7mm for XLumena
Executive Summary
Endoscopic device developer XLumena Inc. raised $7mm in its Series B financing to 11 investors including first-time backers Aperture Venture Partners and Western Technology Investment, and returning shareholders Prism Ventures, Charter Life Sciences, and Ascent Biomedical Ventures. A member from Aperture and Ascent will join XLumena’s board. Funds will support US and European marketing activities for products such as the FDA-approved Navix endoscopy system and CE-Marked Axios stent and delivery system. According to the Form D filing, the company could raise another $1mm before closing the round.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Diagnostic Imaging Equipment & Supplies
- Ultrasound
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice